A Photo-sensitizable Phage for Multidrug-resistant Therapy and Biofilm Ablation
Overview
Authors
Affiliations
Antibiotic abuse causes the emergence of bacterial resistance. Photodynamic antibacterial chemotherapy (PACT) has great potential to solve serious bacterial resistance, but it suffers from the inefficient generation of ROS and the lack of bacterial targeting ability. Herein, a unique cationic photosensitizer (NB) and bacteriophage (ABP)-based photodynamic antimicrobial agent (APNB) is developed for precise bacterial eradication and efficient biofilm ablation. Thanks to the structural modification of the NB photosensitizer with a sulfur atom, it displays excellent reactive oxygen species (ROS)-production ability. Moreover, specific binding to pathogenic microorganisms can be provided by bacteriophages. The developed APNB has multiple functions, including bacteria targeting, near-infrared fluorescence imaging and combination therapy (PACT and phage therapy). Both and experiments prove that APNB can efficiently treat infection. Particularly, the recovery from infection after APNB treatment is faster than that with ampicillin and polymyxin B . Furthermore, the strategy of combining bacteriophages and photosensitizers is employed to eradicate bacterial biofilms for the first time, and it shows the excellent biofilm ablation effect as expected. Thus, APNB has huge potential in fighting against multidrug-resistant bacteria and biofilm ablation in practice.
Su J, Tan Y, Liu S, Zou H, Huang X, Chen S BMC Microbiol. 2025; 25(1):123.
PMID: 40057696 PMC: 11889872. DOI: 10.1186/s12866-025-03854-3.
Palma M, Qi B Infect Dis Rep. 2024; 16(6):1127-1181.
PMID: 39728014 PMC: 11675988. DOI: 10.3390/idr16060092.
Engineering Phages to Fight Multidrug-Resistant Bacteria.
Peng H, Chen I, Qimron U Chem Rev. 2024; 125(2):933-971.
PMID: 39680919 PMC: 11758799. DOI: 10.1021/acs.chemrev.4c00681.
Comprehensive Approaches to Combatting Biofilms: From Biofilm Structure to Phage-Based Therapies.
Grygiel I, Bajrak O, Wojcicki M, Krusiec K, Jonczyk-Matysiak E, Gorski A Antibiotics (Basel). 2024; 13(11).
PMID: 39596757 PMC: 11591314. DOI: 10.3390/antibiotics13111064.
Rastegar S, Skurnik M, Tadjrobehkar O, Samareh A, Samare-Najaf M, Lotfian Z BMC Infect Dis. 2024; 24(1):1208.
PMID: 39455951 PMC: 11515142. DOI: 10.1186/s12879-024-10081-0.